会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Method for providing diagnosis of cancer using seprase as a marker
    • 使用seprase作为标记提供癌症诊断的方法
    • US08980573B2
    • 2015-03-17
    • US12791946
    • 2010-06-02
    • Wolfgang RollingerJohann KarlJarema Peter KochanMarkus RoesslerMichael Tacke
    • Wolfgang RollingerJohann KarlJarema Peter KochanMarkus RoesslerMichael Tacke
    • C12Q1/37G01N33/574
    • G01N33/57423G01N33/57407G01N33/57419G01N33/57473G01N2333/96411
    • The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the human fibroblast activation protein (FAP/seprase) as a universal marker of different cancer types. Seprase aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., esophagus, head and neck cancer, stomach cancer, bile duct cancer, pancreas cancer, kidney cancer, cervix cancer, ovary cancer, breast cancer, bladder cancer, endometrium cancer or prostate cancer. Furthermore, it especially relates to a method for assessing cancer from a liquid sample, derived from an individual by measuring seprase in said sample. Measurement of seprase can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.
    • 本发明涉及一种协助癌症评估的方法。 它公开了使用人成纤维细胞活化蛋白(FAP / seprase)作为不同癌症类型的通用标记物。 Seprase有助于评估肺或肺癌(LC)或结肠癌,例如非小细胞肺癌(NSCLC)或结肠直肠癌(CRC),但也可能是其他特定类型的癌症。 这些特定的癌症类型是例如食管,头颈癌,胃癌,胆管癌,胰腺癌,肾癌,子宫颈癌,卵巢癌,乳腺癌,膀胱癌,子宫内膜癌或前列腺癌。 此外,它特别涉及通过测量所述样品中的seprase从源自个体的液体样品中评估癌症的方法。 seprase的测量可以例如用于癌症的早期检测或用于进行手术的患者的监视。
    • 2. 发明申请
    • SEPRASE AS A MARKER FOR CANCER
    • SEPRASE作为癌症的标记
    • US20100240081A1
    • 2010-09-23
    • US12791946
    • 2010-06-02
    • Wolfgang RollingerJohann KarlJarema Peter KochanMarkus RoesslerMichael Tacke
    • Wolfgang RollingerJohann KarlJarema Peter KochanMarkus RoesslerMichael Tacke
    • C12Q1/48C12Q1/37
    • G01N33/57423G01N33/57407G01N33/57419G01N33/57473G01N2333/96411
    • The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the human fibroblast activation protein (FAP/seprase) as a universal marker of different cancer types. Seprase aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., esophagus, head and neck cancer, stomach cancer, bile duct cancer, pancreas cancer, kidney cancer, cervix cancer, ovary cancer, breast cancer, bladder cancer, endometrium cancer or prostate cancer. Furthermore, it especially relates to a method for assessing cancer from a liquid sample, derived from an individual by measuring seprase in said sample. Measurement of seprase can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.
    • 本发明涉及一种协助癌症评估的方法。 它公开了使用人成纤维细胞活化蛋白(FAP / seprase)作为不同癌症类型的通用标记物。 Seprase有助于评估肺或肺癌(LC)或结肠癌,例如非小细胞肺癌(NSCLC)或结肠直肠癌(CRC),但也可能是其他特定类型的癌症。 这些特定的癌症类型是例如食管,头颈癌,胃癌,胆管癌,胰腺癌,肾癌,子宫颈癌,卵巢癌,乳腺癌,膀胱癌,子宫内膜癌或前列腺癌。 此外,它特别涉及通过测量所述样品中的seprase从源自个体的液体样品中评估癌症的方法。 seprase的测量可以例如用于癌症的早期检测或用于进行手术的患者的监视。